Review Article

Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis

Table 2

Subgroup analysis of pooled HRs and 95% CIs between ALRI and OS and PFS in hepatocellular carcinoma.

VariablesNo. of studiesNo. of patientsEffects modelHR (95% CI)Heterogeneity
2 (%)

OS
 Total113914Random1.53 (1.25-1.82)<0.00180.4<0.001
Treatment
 Surgical resection83218Random1.49 (1.17-1.81)<0.00182.7<0.001
 TACE2267Random2.20 (1.19-3.22)<0.00100.940
 Palliative treatments1429_0.004__
Staging criteria
 AJCC/NA61960Random1.60 (1.38-1.81)<0.00100.823
 BCLC52060Random1.56 (1.20-1.91)<0.00143.30.133
 Milan criteria1241_1.02 (1.01-1.02)<0.001__
Sample size
 <2304664Random1.82 (1.29-2.34)<0.00100.701
 ≥23073250Random1.45 (1.14-1.76)<0.00185.2<0.001
Cut-off value of ALRI
 <2651534Random1.51 (1.21-1.80)<0.00131.40.212
 ≥2662380Random1.54 (1.12-1.96)<0.00183.3<0.001
Cut-off selection
 ROC analysis82501Random1.49 (1.31-1.68)<0.00100.441
 R software1189_2.18 (1.30-3.65)0.003__
 Mean value1241_1.02 (1.01-1.02)<0.001__
 X-tile1983_1.76 (1.42-2.17)<0.001
NOS score
 <82612Random1.24 (0.73-1.76)<0.001840.012
 ≥893302Random1.58 (1.37-1.78)<0.00116.30.298
PFS
 Total72899Random1.36 (1.10-1.63)<0.00181.8<0.001
 Treatment
 Surgical resection62821Random1.35 (1.08-1.61)<0.00184<0.001
 TACE178_2.21 (1.04-4.71)0.040__
Staging criteria
 NA2787Random1.60 (1.31-1.89)<0.00100.521
 BCLC41871Random1.37 (1.18-1.55)<0.00100.651
 Milan criteria1241_1.01 (1.01-1.02)<0.001__
Sample size
 <230178_2.21 (1.04-4.71)0.040__
 ≥23062821Random1.35 (1.08-1.61)<0.00184<0.001
Cut-off value of ALRI
 <2641328Random1.48 (1.21-1.74)<0.00118.70.297
 ≥2631571Random1.24 (0.92-1.57)<0.00185.50.001
Cut-off selection
 ROC analysis51675Random1.46 (1.26-1.66)<0.00100.448
 Mean value1241_1.01 (1.01-1.02)<0.001__
 X-tile1983_1.39 (1.17-1.65)<0.001__
NOS score
 <82612Random1.22 (0.73-1.70)<0.00182.90.016
 ≥851524Random1.42 (1.25-1.58)<0.00100.443